Bonus Biogroup
Sector: Healthcare & Life Sciences
About Bonus Biogroup
Company us Leadership Science and medicine Pipeline BonoFill™ MesenCure™ Cell therapy Tissue engineering Clinical trials Investors Overview Press room In the Media Us Company us Leadership Science and medicine Pipeline BonoFill™ MesenCure™ Cell therapy Tissue engineering Clinical trials Investors Overview Press room In the Media Us US At Bonus Biogroup, we aim to pioneer the future of regenerative medicine. Our groundbreaking technologies and innovative approach are designed to help millions live better and longer lives. At Bonus Biogroup, we aim to pioneer the future of regenerative medicine.
Products
BonoFill™ MesenCure™ Cell therapy Tissue engineering
Bonus Biogroup is developing investigational cell therapy and tissue engineering solutions to address conditions involving tissue damage, bone loss, and inflammation. Our proprietary technology platform supports the clinical development of BonoFill and MesenCure, which are currently undergoing evaluation in clinical studies. BonoFill is being investigated as a patient-specific viable bone graft for maxillofacial, dental, and orthopedic applications. MesenCure is being studied as an allogeneic cell therapy for respiratory distress and other inflammatory conditions. Additional research is ongoing to explore new therapeutic indications.